Artelo Biosciences, Inc
artelobio.comWhat Do They Do?
Develops prescription medicines that target lipid-signaling pathways, including cannabinoid and fatty-acid-binding-protein programs, for people with cancer, pain, and other conditions.
10-K for FY2025, filed Feb 24, 2026We incorporated in the State of Nevada on May 2, 2011, and are presently based in the County of San Diego, California. We are a clinical…View ↗
We are currently developing a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors.…View ↗
Our second program, ART26.12 is a small molecule and the lead product candidate from our chemical library of inhibitors of fatty acid…View ↗
ART12.11 is our wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 24, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$2.4MView ↗
- ▼ −25% (Loss)
- vs −$3.2M in Q2 FY2025
-
Aug 27, 2026
Artelo announced a reverse stock split.
Every nine shares will combine into one share, with split-adjusted trading expected to begin August 31, 2026.
Sources
8-K, filed Aug 27, 2026
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026View ↗
-
May 27, 2026
Artelo established an at-the-market stock offering program.
The company may sell up to $6,530,000 of shares through H.C. Wainwright from time to time.
Sources
8-K, filed May 27, 2026
On May 26, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with…View ↗
-
Mar 30, 2026
Artelo completed a private placement of shares and warrants.
The offering generated gross proceeds of $10,996,902.70 before fees and expenses.
Sources
8-K, filed Mar 30, 2026
The gross proceeds from the Offering, before deducting Placement Agent fees and other offering expenses payable by the Company, were…View ↗
-
Mar 26, 2026
Artelo expanded ART27.13 research toward preserving muscle during GLP-1 treatment.
The company began a non-clinical study and filed a provisional patent application for this potential use.
Sources
8-K, filed Mar 26, 2026
On March 25, 2026, the Company issued a press release to announce a strategic expansion opportunity for ART27.13 in muscle preservation for…View ↗
Who Do They Compete With?
Competes with Novartis International, Helsinn Therapeutics (U.S.), NGM Biopharmaceuticals, Jazz Pharmaceuticals, Skye Bioscience, Longboard Pharmaceuticals, and Pfizer
10-K for FY2025, filed Feb 24, 2026Our potential competitors, which include pharmaceutical and biopharmaceutical companies such as Novartis International AG, Helsinn…View ↗
Loading...
